Skip to main content

UNITED THERAPEUTICS Corp

For the period ended Mar 31, 2026. Filed May 6, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 6, 2026

UTHR$582.46+3.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 6. Exhibits

Exhibit No.Description
3.1Restated Certificate of Incorporation of the Registrant, incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed October 1, 2021
3.2Eleventh Amended and Restated Bylaws of the Registrant, incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed January 22, 2026
4.1Reference is made to Exhibits 3.1 and 3.2
31.1*Certification of Principal Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934
31.2*Certification of Principal Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934
32.1**Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2**Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101*The following financial information from our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 6, 2026, formatted in Inline Extensible Business Reporting Language (iXBRL): (1) our Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025; (2) our Consolidated Statements of Operations for the three-month periods ended March 31, 2026 and 2025; (3) our Consolidated Statements of Comprehensive Income for the three-month periods ended March 31, 2026 and 2025; (4) our Consolidated Statements of Stockholders’ Equity for the three-month periods ended March 31, 2026 and 2025; (5) our Consolidated Statements of Cash Flows for the three-month periods ended March 31, 2026 and 2025; and (6) the Notes to our Consolidated Financial Statements.
104*Cover Page Interactive Data File (embedded within the iXBRL document)
  • Filed herewith.

** Furnished herewith.

Note: Except as otherwise noted above, all exhibits incorporated by reference to the Registrant’s previously filed reports with the Securities and Exchange Commission are filed under File No. 000-26301.

Quarterly Report53
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.